Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
A recent phase 3 trial demonstrates that a combination therapy of belantamab mafodotin, bortezomib, and dexamethasone leads to significantly longer progression-free survival in patients with relapsed or refractory multiple myeloma compared to a regimen including daratumumab.
Hematology/Oncology June 10th 2024
GoodRx Health
Several medications, including antihistamines, muscle relaxers, and benzodiazepines, are known to cause fatigue. Understanding these effects and managing patient expectations can help mitigate this common side effect.
All Specialties June 4th 2024
Oncology News Central (ONC)
MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.
Oncology, Medical June 4th 2024
Interim results from J&J’s Phase I study of JNJ-6420 highlight both promising efficacy in prostate cancer treatment and serious safety concerns, with 60% of patients experiencing severe adverse events.
Oncology, Medical June 3rd 2024
A case of pacemaker-lead dislodgement with cardiac perforation in a 96-year-old patient highlights the importance of recognizing and addressing complications swiftly to prevent severe outcomes.
Cardiology May 22nd 2024
Healthline
Patients on GLP-1 medications may experience notable changes in breast morphology, such as decreased volume and increased sagging. Medical experts recommend supportive measures and a stable weight before considering surgical interventions.
Obstetrics & Gynecology May 17th 2024